174 related articles for article (PubMed ID: 30964199)
21. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
[No Abstract] [Full Text] [Related]
23. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
26. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
Garcia CA; Dacic S; Villaruz LC
J Thorac Oncol; 2018 Aug; 13(8):e135-e136. PubMed ID: 30049372
[No Abstract] [Full Text] [Related]
27. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
Totonchy MB; Ezaldein HH; Ko CJ; Choi JN
JAMA Dermatol; 2016 May; 152(5):590-2. PubMed ID: 26675815
[No Abstract] [Full Text] [Related]
28. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
[No Abstract] [Full Text] [Related]
29. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
30. Erythromelanosis follicularis faciei et colli: A clinicoepidemiologic study.
Arif T; Adil M; Amin SS; Tahseen M; Dorjay K; Mohtashim M; Singh M; Bansal R; Raj D
Pediatr Dermatol; 2018 Jan; 35(1):e70-e71. PubMed ID: 29164663
[TBL] [Abstract][Full Text] [Related]
31. Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for non-small-cell lung cancer.
Stigt JA; Boomsma MF; de Vos tot Nederveen Cappel WH
J Thorac Oncol; 2013 Mar; 8(3):e25-6. PubMed ID: 23407564
[No Abstract] [Full Text] [Related]
32. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial.
Tyagi P
Clin Lung Cancer; 2005 Mar; 6(5):276-8. PubMed ID: 15845177
[No Abstract] [Full Text] [Related]
33. Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab.
Koczywas M; Cristea MC
J Thorac Oncol; 2011 Nov; 6(11):1960-1. PubMed ID: 22005475
[No Abstract] [Full Text] [Related]
34. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.
Katsenos S; Christophylakis C; Psathakis K
Arch Bronconeumol; 2012 Jun; 48(6):218-9. PubMed ID: 22429334
[No Abstract] [Full Text] [Related]
35. In focus: non-small cell lung cancer: E1505.
Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
[No Abstract] [Full Text] [Related]
36. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
37. Rapid Response to Pembrolizumab in a Critically Ill Mechanically Ventilated Patient with New Diagnosis of NSCLC.
McLoughlin EM; Larner JM; Bergman MP; Stelow EB; Brady K; Lynch AC; Abraham RS; Gentzler RD
J Thorac Oncol; 2019 Sep; 14(9):e193-e195. PubMed ID: 31445732
[No Abstract] [Full Text] [Related]
38. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
Ninomiya K; Hotta K
Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
[TBL] [Abstract][Full Text] [Related]
39. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC.
Artal-Cortés A; Felices-Lobera P; Márquez-Medina D
J Thorac Oncol; 2018 May; 13(5):e76-e77. PubMed ID: 29703541
[No Abstract] [Full Text] [Related]
40. Preliminary experience with bevacizumab in combination with standard chemotherapeutic regimens in the treatment of non-small cell lung cancer: a retrospective study.
Emmanouilides C; Philippou D; Sapountzi E; Diamandidou E
Hematol Oncol Stem Cell Ther; 2008; 1(3):183-8. PubMed ID: 20063550
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
